Inhibition of human neutrophil binding to hydrogen peroxide-treated endothelial cells by cAMP and hydroxyl radical scavengers.
Hydrogen peroxide (H2O2) increases adherence of human polymorphonuclear neutrophils (PMN) to cultured human umbilical vein endothelial cells (HUVEC). Catalase and HO. scavengers did not affect the increased PMN adherence to HUVEC stimulated by other compounds such as phorbol myristate acetate (PMA) and thrombin, showing that the observed effect was H2O2- and HO.-specific. This effect was inhibited by hydroxyl radicals (HO.) scavengers and not by iron-chelators that do not penetrate the cells, suggesting the involvement of intracellular HO. in the increased adherence mechanism. An increase in cAMP inhibited H2O2-induced adherence, as observed with isoproterenol, isobutylmethylxanthine, and dibutyryl-cAMP. Similarly, pentoxifylline (Ptx), an HO. scavenger that also increases cAMP, inhibited H2O2-mediated adherence but had no effect on that induced by PMA or thrombin. PKA inhibitors cancelled the Ptx-induced inhibition of H2O2-mediated adherence. However, PKA inhibitors or atrial natriuretic peptide that decreases cAMP did not increase adherence, showing that decrease in cAMP is not responsible for increased adherence. HO. scavengers did not alter the H2O2-induced reduction in cAMP levels, but did inhibit the effect of H2O2 on adherence. We conclude that HO. mediates the H2O2-induced increased in PMN adherence to HUVEC, and that the increase in cAMP that mediates PKA activation downregulates this effect.
Franzini
E
E
INSERM U294, CHU Xavier Bichat, Université Paris, France.
Sellak
H
H
Marquetty
C
C
Babin-Chevaye
C
C
Hakim
J
J
Pasquier
C
C
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000704:Analysis of Variance; D003994:Bucladesine / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism*; D003676:Deferoxamine / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000502:physiology*; D016166:Free Radical Scavengers / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology*; D017665:Hydroxyl Radical; D019271:Hypoxanthine / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010431:Pentoxifylline / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology; D014168:Transferrin / Q000494:pharmacology; D014471:Umbilical Veins; D014969:Xanthine Oxidase / Q000494:pharmacology
D016166:Free Radical Scavengers; D014168:Transferrin; D019271:Hypoxanthine; D017665:Hydroxyl Radical; D003994:Bucladesine; D006861:Hydrogen Peroxide; D000242:Cyclic AMP; D014969:Xanthine Oxidase; D013917:Thrombin; D005978:Glutathione; D003676:Deferoxamine; D007545:Isoproterenol; D013755:Tetradecanoylphorbol Acetate; D010431:Pentoxifylline; D015056:1-Methyl-3-isobutylxanthine